NCT02211261 is a Phase 1 clinical trial of PF-06293620 in Type 2 Diabetes Mellitus, sponsored by Pfizer.

Who is sponsoring NCT02211261?

NCT02211261 is sponsored by Pfizer.

What drugs are being tested in NCT02211261?

Interventions in NCT02211261: PF-06293620, Placebo, PF-06293620, Placebo, PF-06293620, Placebo, PF-06293620, Placebo, PF-06293620, Placebo, PF-06293620, Placebo, PF-06293620, Placebo, PF-06293620, Placebo, PF-06293620, Placebo.

What condition does NCT02211261 study?

NCT02211261 studies Type 2 Diabetes Mellitus.

Is NCT02211261 still recruiting?

NCT02211261 is currently completed. Last updated 16 October 2018.

Are results published for NCT02211261?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2018-10-16 · How we verify

NCT02211261

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase 1 Single/Multiple Dose Study Of PF-06293620 To Assess Safety, Tolerability And Pharmacokinetics In Subjects With Type 2 Diabetes Mellitus

Completed Phase 1 Results posted Last updated 16 October 2018

What this trial tests

Phase 1 trial testing PF-06293620 in Type 2 Diabetes Mellitus in 84 participants. Completed in 27 January 2017.

Timeline

15 September 2014

Primary endpoint
27 January 2017

27 January 2017

Quick facts

Lead sponsor	Pfizer
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	basic science
Enrollment	84
Start date	15 September 2014
Primary completion	27 January 2017
Estimated completion	27 January 2017
Sites	7 locations across United States

Drugs / interventions tested

PF-06293620 — full drug profile →
Placebo
PF-06293620 — full drug profile →
Placebo
PF-06293620 — full drug profile →
Placebo
PF-06293620 — full drug profile →
Placebo
PF-06293620 — full drug profile →
Placebo
PF-06293620 — full drug profile →
Placebo
PF-06293620 — full drug profile →
Placebo
PF-06293620 — full drug profile →
Placebo
PF-06293620 — full drug profile →
Placebo

Conditions studied

Type 2 Diabetes Mellitus — all drugs for Type 2 Diabetes Mellitus →

Sponsor

Pfizer — full company profile →

Who can join

Adults 18 to 70, any sex, with Type 2 Diabetes Mellitus. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Number of Participants With All-Causality and Treatment Related Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events Primary · Days 1 to 85 for SAD cohorts and Days 1 to 169 for MAD cohorts; participants with positive anti-drug antibody (ADA) results were followed up to stabilization of ADA titers or up to 9 months after Day 169 visit.

An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a product or medical device, regardless of its causal relationship with study treatment. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; was life-threatening (immediate risk of death); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs are events between first dose of study drug and up to Day 85 (for SAD cohorts) o

All-causality AE

Group	Value	95% CI
Placebo SC (SAD Cohorts)	5
PF-06293620 0.3 mg/kg SC (SAD Cohorts)	3
PF-06293620 1.0 mg/kg SC (SAD Cohorts)	3
PF-06293620 3.0 mg/kg SC (SAD Cohorts)	5
PF-06293620 6.0 mg/kg SC (SAD Cohorts)	5
Placebo IV (SAD Cohorts)	0
PF-06293620 1.0 mg/kg IV (SAD Cohorts)	3
Placebo SC (MAD Cohorts)	4
PF-06293620 50 mg SC (MAD Cohorts)	4
PF-06293620 75 mg SC (MAD Cohorts)	11
PF-06293620 150 mg SC (MAD Cohorts)	8

All-causality SAE

Group	Value	95% CI
Placebo SC (SAD Cohorts)	0
PF-06293620 0.3 mg/kg SC (SAD Cohorts)	1
PF-06293620 1.0 mg/kg SC (SAD Cohorts)	0
PF-06293620 3.0 mg/kg SC (SAD Cohorts)	0
PF-06293620 6.0 mg/kg SC (SAD Cohorts)	0
Placebo IV (SAD Cohorts)	0
PF-06293620 1.0 mg/kg IV (SAD Cohorts)	0
Placebo SC (MAD Cohorts)	0
PF-06293620 50 mg SC (MAD Cohorts)	0
PF-06293620 75 mg SC (MAD Cohorts)	1
PF-06293620 150 mg SC (MAD Cohorts)	2

Treatment-related AE

Group	Value	95% CI
Placebo SC (SAD Cohorts)	1
PF-06293620 0.3 mg/kg SC (SAD Cohorts)	0
PF-06293620 1.0 mg/kg SC (SAD Cohorts)	0
PF-06293620 3.0 mg/kg SC (SAD Cohorts)	3
PF-06293620 6.0 mg/kg SC (SAD Cohorts)	3
Placebo IV (SAD Cohorts)	0
PF-06293620 1.0 mg/kg IV (SAD Cohorts)	1
Placebo SC (MAD Cohorts)	1
PF-06293620 50 mg SC (MAD Cohorts)	1
PF-06293620 75 mg SC (MAD Cohorts)	4
PF-06293620 150 mg SC (MAD Cohorts)	5

Treatment-related SAE

Group	Value	95% CI
Placebo SC (SAD Cohorts)	0
PF-06293620 0.3 mg/kg SC (SAD Cohorts)	0
PF-06293620 1.0 mg/kg SC (SAD Cohorts)	0
PF-06293620 3.0 mg/kg SC (SAD Cohorts)	0
PF-06293620 6.0 mg/kg SC (SAD Cohorts)	0
Placebo IV (SAD Cohorts)	0
PF-06293620 1.0 mg/kg IV (SAD Cohorts)	0
Placebo SC (MAD Cohorts)	0
PF-06293620 50 mg SC (MAD Cohorts)	0
PF-06293620 75 mg SC (MAD Cohorts)	0
PF-06293620 150 mg SC (MAD Cohorts)	0

Number of Participants With Positive Anti-drug Antibody (ADA) Result Primary · Days 1 to 85 for SAD cohorts; Days 1 to 169 for MAD Cohorts

ADA against PF-06293620 in human serum samples was determined following a tiered approach using screening, confirmation, and titer/quantification by semi-quantitative enzyme linked immunosorbent assay (ELISA). Endpoint titer \>=1.88 was considered positive.

Group	Value	95% CI
Placebo SC (SAD Cohorts)	1
PF-06293620 0.3 mg/kg SC (SAD Cohorts)	5
PF-06293620 1.0 mg/kg SC (SAD Cohorts)	2
PF-06293620 3.0 mg/kg SC (SAD Cohorts)	1
PF-06293620 6.0 mg/kg SC (SAD Cohorts)	2
Placebo IV (SAD Cohorts)	0
PF-06293620 1.0 mg/kg IV (SAD Cohorts)	1
Placebo SC (MAD Cohorts)	0
PF-06293620 50 mg SC (MAD Cohorts)	5
PF-06293620 75 mg SC (MAD Cohorts)	7
PF-06293620 150 mg SC (MAD Cohorts)	4

Area Under the Serum Concentration-Time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) of PF-06293620 (SAD Cohorts) Secondary · Pre-dose, 1, 4, 8 and 12 hours post-dose on Day 1; 24 and 36 hours post-dose on Day 2; Days 3, 4, 5, 8, 15, 22, 29, 43, 57, 85

AUCinf was calculated as AUClast +(Clast\*/kel), where AUClast is area under the serum concentration-time profile from time 0 to the time of the last quantifiable concentration, Clast\* is the predicted serum concentration at the last quantifiable time point estimated from the log-linear regression analysis, kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve. Only those data points judged to describe the terminal log-linear decline were used in the regression.

Group	Value	95% CI
PF-06293620 0.3 mg/kg SC (SAD Cohorts)	300	± NA
PF-06293620 1.0 mg/kg SC (SAD Cohorts)	1716	± 46
PF-06293620 3.0 mg/kg SC (SAD Cohorts)	6306	± 54
PF-06293620 6.0 mg/kg SC (SAD Cohorts)	19440	± 56
PF-06293620 1.0 mg/kg IV (SAD Cohorts)	6775	± 12

Dose-normalized AUCinf (AUCinf(dn)) of PF-06293620 (SAD Cohorts) Secondary · Pre-dose, 1, 4, 8 and 12 hours post-dose on Day 1; 24 and 36 hours post-dose on Day 2; Days 3, 4, 5, 8, 15, 22, 29, 43, 57, 85

AUCinf(dn) was calculated as AUCinf/dose, where AUCinf is area under the serum concentration-time profile from time 0 extrapolated to infinite time.

Group	Value	95% CI
PF-06293620 0.3 mg/kg SC (SAD Cohorts)	12.00	± NA
PF-06293620 1.0 mg/kg SC (SAD Cohorts)	22.24	± 45
PF-06293620 3.0 mg/kg SC (SAD Cohorts)	23.79	± 47
PF-06293620 6.0 mg/kg SC (SAD Cohorts)	36.13	± 49
PF-06293620 1.0 mg/kg IV (SAD Cohorts)	67.94	± 16

Area Under the Serum Concentration-Time Profile From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of PF-06293620 (SAD Cohorts) Secondary · Pre-dose, 1, 4, 8 and 12 hours post-dose on Day 1; 24 and 36 hours post-dose on Day 2; Days 3, 4, 5, 8, 15, 22, 29, 43, 57, 85

Area under the serum concentration-time profile from time 0 to the time of the last quantifiable concentration (AUClast) of PF-06293620 was determined using linear/log trapezoidal method.

Group	Value	95% CI
PF-06293620 0.3 mg/kg SC (SAD Cohorts)	128.3	± 54
PF-06293620 1.0 mg/kg SC (SAD Cohorts)	1619	± 46
PF-06293620 3.0 mg/kg SC (SAD Cohorts)	5945	± 53
PF-06293620 6.0 mg/kg SC (SAD Cohorts)	18080	± 58
PF-06293620 1.0 mg/kg IV (SAD Cohorts)	6509	± 13

Dose-normalized AUClast (AUClast(dn)) of PF-06293620 (SAD Cohorts) Secondary · Pre-dose, 1, 4, 8 and 12 hours post-dose on Day 1; 24 and 36 hours post-dose on Day 2; Days 3, 4, 5, 8, 15, 22, 29, 43, 57, 85

AUClast(dn) of PF-06293620 was calculated as AUClast/dose, where AUClast was area under the serum concentration-time profile from time 0 to the time of the last quantifiable concentration.

Group	Value	95% CI
PF-06293620 0.3 mg/kg SC (SAD Cohorts)	4.779	± 58
PF-06293620 1.0 mg/kg SC (SAD Cohorts)	21.01	± 44
PF-06293620 3.0 mg/kg SC (SAD Cohorts)	22.47	± 47
PF-06293620 6.0 mg/kg SC (SAD Cohorts)	33.59	± 50
PF-06293620 1.0 mg/kg IV (SAD Cohorts)	65.26	± 18

Clearance (CL) of PF-06293620 (SAD Cohorts) Secondary · Pre-dose, 1, 4, 8 and 12 hours post-dose on Day 1; 24 and 36 hours post-dose on Day 2; Days 3, 4, 5, 8, 15, 22, 29, 43, 57, 85

Clearance (CL) was calculated as dose/AUCinf, where AUCinf was area under the serum concentration-time profile from time 0 extrapolated to infinite time. This outcome measure only applies to IV arms.

Group	Value	95% CI
PF-06293620 1.0 mg/kg IV (SAD Cohorts)	14.72	± 16

Apparent Clearance (CL/F) of PF-06293620 (SAD Cohorts) Secondary · Pre-dose, 1, 4, 8 and 12 hours post-dose on Day 1; 24 and 36 hours post-dose on Day 2; Days 3, 4, 5, 8, 15, 22, 29, 43, 57, 85

Apparent Clearance (CL/F) of PF-06293620 was calculated as dose/AUCinf, where AUCinf was area under the serum concentration-time profile from time 0 extrapolated to infinite time. This outcome measure only applies to SC arms.

Group	Value	95% CI
PF-06293620 0.3 mg/kg SC (SAD Cohorts)	83.20	± NA
PF-06293620 1.0 mg/kg SC (SAD Cohorts)	44.93	± 45
PF-06293620 3.0 mg/kg SC (SAD Cohorts)	42.05	± 47
PF-06293620 6.0 mg/kg SC (SAD Cohorts)	27.67	± 49

Maximum Serum Concentration (Cmax) of PF-06293620 (SAD Cohorts) Secondary · Pre-dose, 1, 4, 8 and 12 hours post-dose on Day 1; 24 and 36 hours post-dose on Day 2; Days 3, 4, 5, 8, 15, 22, 29, 43, 57, 85

Maximum serum concentration (Cmax) of PF-06293620 was observed directly from data.

Group	Value	95% CI
PF-06293620 0.3 mg/kg SC (SAD Cohorts)	0.3907	± 58
PF-06293620 1.0 mg/kg SC (SAD Cohorts)	2.896	± 48
PF-06293620 3.0 mg/kg SC (SAD Cohorts)	7.222	± 52
PF-06293620 6.0 mg/kg SC (SAD Cohorts)	22.30	± 62
PF-06293620 1.0 mg/kg IV (SAD Cohorts)	27.64	± 20

Time for Maximum Serum Concentration (Tmax) of PF-06293620 (SAD Cohorts) Secondary · Pre-dose, 1, 4, 8 and 12 hours post-dose on Day 1; 24 and 36 hours post-dose on Day 2; Days 3, 4, 5, 8, 15, 22, 29, 43, 57, 85

Time for Maximum serum concentration (Tmax) of PF-06293620 was observed directly from data as time of first occurrence.

Group	Value	95% CI
PF-06293620 0.3 mg/kg SC (SAD Cohorts)	168	71.9 – 336
PF-06293620 1.0 mg/kg SC (SAD Cohorts)	168	48.0 – 504
PF-06293620 3.0 mg/kg SC (SAD Cohorts)	252	95.9 – 504
PF-06293620 6.0 mg/kg SC (SAD Cohorts)	168	96.0 – 504
PF-06293620 1.0 mg/kg IV (SAD Cohorts)	1.00	1.00 – 2.00

Steady-state Volume of Distribution (Vss) of PF-06293620 (SAD Cohorts) Secondary · Pre-dose, 1, 4, 8 and 12 hours post-dose on Day 1; 24 and 36 hours post-dose on Day 2; Days 3, 4, 5, 8, 15, 22, 29, 43, 57, 85

Steady-state volume of distribution (Vss) of PF-06293620 was calculated as CL\*MRT, where MRT was the mean residence time calculated as (AUMCinf/AUCinf - infusion duration/2), AUMCinf was area under the moment curve from time 0 extrapolated to infinity; CL was the clearance. This outcome measure only applies to IV arms.

Group	Value	95% CI
PF-06293620 1.0 mg/kg IV (SAD Cohorts)	7.095	1.00 – 2.00

Apparent Volume of Distribution (Vz/F) of PF-06293620 (SAD Cohorts) Secondary · Pre-dose, 1, 4, 8 and 12 hours post-dose on Day 1; 24 and 36 hours post-dose on Day 2; Days 3, 4, 5, 8, 15, 22, 29, 43, 57, 85

Apparent Volume of Distribution (Vz/F) of PF-06293620 was calculated as dose/(AUCinf\*kel), where AUCinf was area under the serum concentration-time profile from time 0 extrapolated to infinite time, kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve. This outcome measure only applies to SC arms.

Group	Value	95% CI
PF-06293620 0.3 mg/kg SC (SAD Cohorts)	21.10	± NA
PF-06293620 1.0 mg/kg SC (SAD Cohorts)	16.25	± 43
PF-06293620 3.0 mg/kg SC (SAD Cohorts)	20.63	± 44
PF-06293620 6.0 mg/kg SC (SAD Cohorts)	18.17	± 48

Adverse events — posted to ClinicalTrials.gov

Time frame: Days 1 to 85 for SAD cohorts and Days 1 to 169 for MAD cohorts; participants with positive anti-drug antibody (ADA) results were followed up to stabilization of ADA titers or up to 9 months after Day 169 visit.. Reporting threshold: 5%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Placebo SC (SAD Cohorts)

Serious: 0/9 (0%)

Deaths: 0/9

PF-06293620 0.3 mg/kg SC (SAD Cohorts)

Serious: 1/6 (17%)

Deaths: 0/6

PF-06293620 1.0 mg/kg SC (SAD Cohorts)

Serious: 0/6 (0%)

Deaths: 0/6

PF-06293620 3.0 mg/kg SC (SAD Cohorts)

Serious: 0/6 (0%)

Deaths: 0/6

PF-06293620 6.0 mg/kg SC (SAD Cohorts)

Serious: 0/9 (0%)

Deaths: 0/9

Placebo IV (SAD Cohorts)

Serious: 0/2 (0%)

Deaths: 0/2

PF-06293620 1.0 mg/kg IV (SAD Cohorts)

Serious: 0/6 (0%)

Deaths: 0/6

Placebo SC (MAD Cohorts)

Serious: 0/8 (0%)

Deaths: 0/8

PF-06293620 50 mg SC (MAD Cohorts)

Serious: 0/8 (0%)

Deaths: 0/8

PF-06293620 75 mg SC (MAD Cohorts)

Serious: 1/16 (6%)

Deaths: 0/16

PF-06293620 150 mg SC (MAD Cohorts)

Serious: 2/8 (25%)

Deaths: 0/8

Serious adverse events (4 terms)

Reaction	System	Placebo SC (SAD Cohorts)	PF-06293620 0.3 mg/kg SC (…	PF-06293620 1.0 mg/kg SC (…	PF-06293620 3.0 mg/kg SC (…	PF-06293620 6.0 mg/kg SC (…	Placebo IV (SAD Cohorts)	PF-06293620 1.0 mg/kg IV (…	Placebo SC (MAD Cohorts)	PF-06293620 50 mg SC (MAD …	PF-06293620 75 mg SC (MAD …	PF-06293620 150 mg SC (MAD…
Cholelithiasis	Hepatobiliary disorders	—	—	—	—	—	—	—	—	—	—	—
Angina unstable	Cardiac disorders	—	—	—	—	—	—	—	—	—	—	—
Coronary artery disease	Cardiac disorders	—	—	—	—	—	—	—	—	—	—	—
Joint injury	Injury, poisoning and procedural complications	—	—	—	—	—	—	—	—	—	—	—

Other adverse events (60 terms — click to expand)

Reaction	System	Placebo SC (SAD Cohorts)	PF-06293620 0.3 mg/kg SC (…	PF-06293620 1.0 mg/kg SC (…	PF-06293620 3.0 mg/kg SC (…	PF-06293620 6.0 mg/kg SC (…	Placebo IV (SAD Cohorts)	PF-06293620 1.0 mg/kg IV (…	Placebo SC (MAD Cohorts)	PF-06293620 50 mg SC (MAD …	PF-06293620 75 mg SC (MAD …	PF-06293620 150 mg SC (MAD…
Liver function test increased	Investigations	—	—	—	—	—	—	—	—	—	—	—
Iron deficiency anaemia	Blood and lymphatic system disorders	—	—	—	—	—	—	—	—	—	—	—
Diarrhoea	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—
Fall	Injury, poisoning and procedural complications	—	—	—	—	—	—	—	—	—	—	—
Ecchymosis	Skin and subcutaneous tissue disorders	—	—	—	—	—	—	—	—	—	—	—
Abdominal distension	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—
Abdominal pain	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—
Abdominal pain lower	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—
Abdominal pain upper	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—
Constipation	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—
Dry mouth	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—
Flatulence	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—
Gastrooesophageal reflux disease	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—
Toothache	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—
Vomiting	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—
Asthenia	General disorders	—	—	—	—	—	—	—	—	—	—	—
Hunger	General disorders	—	—	—	—	—	—	—	—	—	—	—
Infusion site extravasation	General disorders	—	—	—	—	—	—	—	—	—	—	—
Infusion site hemorrhage	General disorders	—	—	—	—	—	—	—	—	—	—	—
Injection site pruritus	General disorders	—	—	—	—	—	—	—	—	—	—	—
Malaise	General disorders	—	—	—	—	—	—	—	—	—	—	—
Biliary colic	Hepatobiliary disorders	—	—	—	—	—	—	—	—	—	—	—
Nausea	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—
Cholelithiasis	Hepatobiliary disorders	—	—	—	—	—	—	—	—	—	—	—
Body tinea	Infections and infestations	—	—	—	—	—	—	—	—	—	—	—
Bronchitis	Infections and infestations	—	—	—	—	—	—	—	—	—	—	—
Cellulitis	Infections and infestations	—	—	—	—	—	—	—	—	—	—	—
Infective glossitis	Infections and infestations	—	—	—	—	—	—	—	—	—	—	—
Influenza	Infections and infestations	—	—	—	—	—	—	—	—	—	—	—
Pharyngitis	Infections and infestations	—	—	—	—	—	—	—	—	—	—	—
Upper respiratory tract infection	Infections and infestations	—	—	—	—	—	—	—	—	—	—	—
Viral pharyngitis	Infections and infestations	—	—	—	—	—	—	—	—	—	—	—
Sinusitis	Infections and infestations	—	—	—	—	—	—	—	—	—	—	—
Viral infection	Infections and infestations	—	—	—	—	—	—	—	—	—	—	—
Viral upper respiratory tract infection	Infections and infestations	—	—	—	—	—	—	—	—	—	—	—
Blood creatine phosphokinase increased	Investigations	—	—	—	—	—	—	—	—	—	—	—
Blood pressure increased	Investigations	—	—	—	—	—	—	—	—	—	—	—
Haemoglobin decreased	Investigations	—	—	—	—	—	—	—	—	—	—	—
Gout	Metabolism and nutrition disorders	—	—	—	—	—	—	—	—	—	—	—
Decreased appetite	Metabolism and nutrition disorders	—	—	—	—	—	—	—	—	—	—	—

Most-reported serious reactions: Cholelithiasis, Angina unstable, Coronary artery disease, Joint injury.

Data from ClinicalTrials.gov NCT02211261 adverse events section.

Sponsor's own description

A first in human study to determine the safety, tolerability and pharmacokinetics of single and multiple ascending doses of PF-06293620 in subjects with Type 2 Diabetes Mellitus

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Pancreatic endocrine and exocrine signaling and crosstalk in physiological and pathological status.
Hu C, Chen Y, Yin X, Xu R, et al · · 2025 · cited 25× · PMID 39948335 · DOI 10.1038/s41392-024-02098-3
The Role of the α Cell in the Pathogenesis of Diabetes: A World beyond the Mirror.
Martínez MS, Manzano A, Olivar LC, Nava M, et al · · 2021 · cited 18× · PMID 34502413 · DOI 10.3390/ijms22179504

Verify or expand the search:

Other recruiting trials for Type 2 Diabetes Mellitus

Currently open trials in the same condition.

NCT07351058 — A Clinical Study to Evaluate the Effects of RO7795068 in Participants With Obesity or Overweight and Type 2 Diabetes · Phase 3 · recruiting
NCT07373938 — Carotid Wall Texture as a Cardiovascular Risk Biomarker in Type 2 Diabetes Mellitus · recruiting
NCT07433062 — A Study to Evaluate the Effect of AZD6793 on the Pharmacokinetics and Pharmacodynamics of Metformin in Participants With · Phase 1 · recruiting
NCT07276776 — An Evaluation of the Omnipod® M System in Adults With Type 2 Diabetes · NA · active not recruiting
NCT07232537 — An Observational Study Called FINE-REAL Korea to Learn More About the Use of the Drug Finerenone in People With Chronic · recruiting

Other Pfizer trials

Trials by the same sponsor.

NCT04982848 — Korea Post Marketing Surveillance (PMS) Study of Talzenna® · not yet recruiting
NCT06873191 — A Study to Learn More About Tukysa Once it is Out in the Korean Market · not yet recruiting
NCT07497854 — A Study to Learn About the Study Medicine NURTEC® ODT 75 mg After it is Released Into the Markets in Korea · not yet recruiting
NCT06507904 — A Study to Learn How Different Preparations of Osivelotor Taste and Enter the Blood With Food or Liquids or With an Anta · Phase 1 · not yet recruiting
NCT06864585 — A Study to Learn About the Study Medicine - Zavicefta in Patients With Sepsis or Loss of Kidney Function in Japan · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02211261 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Pfizer
Last refreshed: 16 October 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02211261.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing

NCT02211261

Quick facts

Drugs / interventions tested

Conditions studied

Sponsor

Who can join

Results — posted to ClinicalTrials.gov

Adverse events — posted to ClinicalTrials.gov

Serious adverse events (4 terms)

Sponsor's own description

Publications & conference data

Related trials

Other recruiting trials for Type 2 Diabetes Mellitus

Other Pfizer trials

Verify against primary sources